AlphAIalphai — Financial news for AI agents
rttnews.comSEP 32 min read$ABBV

AbbVie Completes $10.9 Bln Acquisition Of Apogee Therapeutics

AbbVie (ABBV) completed its $10.9 billion acquisition of Apogee Therapeutics (APGE), paying $135.11 per share. The deal strengthens AbbVie's immunology pipeline, including Apogee's lead asset, zumilokibart, for atopic dermatitis. AbbVie expects the acquisition to be dilutive to earnings until 2032. AbbVie reaffirmed its 2026 EPS guidance of $13.87-$14.07, including a $0.14 per-share dilutive impact. ABBV closed at $261.72, up 0.67%.

Original reporting
rttnews.com
Published Sep 3, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 3, 2026, 4:22 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
AbbVie Completes $10.9 Bln Acquisition Of Apogee Therapeutics — source image
Source · rttnews.com
Decision brief

The 30-second read

$ABBVNeutralHigh
01

Why it matters

The transaction adds late‑stage assets to AbbVie's portfolio and adjusts EPS guidance, influencing valuation models.

02

Market read

A major pharma M&A event with immediate EPS guidance impact and share‑price movement.

03

What to watch

Potential integration challenges and regulatory scrutiny.

Relevance 9/10Novelty 9/10Timing: pre‑market today

Background

AbbVie announced the completion of its acquisition of Apogee Therapeutics, a biotech focused on inflammatory diseases.

Company-level read

Ticker impact

$ABBVNeutralHigh confidence
Context

AbbVie completed its $10.9 billion acquisition of Apogee Therapeutics, impacting EPS guidance and share price.

Expected impact

Slight upside as market digests deal completion.

Evidence & confidence

Deal size and EPS guidance change are material and newly disclosed.

$APGENeutralHigh confidence
Context

Apogee Therapeutics ceased trading after being acquired by AbbVie for $135.11 per share.

Expected impact

No further price action; investors receive cash.

Evidence & confidence

Acquisition completion and cash payout are definitive.

Market effects

Sector

Strengthens AbbVie's immunology franchise, may pressure peers.

Regional

U.S. biotech sector sees modest uplift.

Global

Large‑cap pharma M&A adds to overall deal activity metrics.

Counterpoint

What could challenge this read

Deal may overpay for Apogee's pipeline given execution risk.

Key entities

  • Company
    AbbVie Inc.

    Acquirer, US‑listed pharmaceutical company.

  • Company
    Apogee Therapeutics, Inc.

    Target, now integrated into AbbVie.

Read at source← All news

Related articles

SEP 3
$ABBVMedAI 9/10

AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multi

AbbVie (ABBV) reported positive Phase 3 trial results for etentamig, showing a 74% objective response rate and 60% risk reduction in disease progression in relapsed/refractory multiple myeloma patients. The study met primary endpoints of ORR and PFS, with manageable safety profile. Full results will be presented at the 23rd International Myeloma Society Annual Meeting in 2026.

investingnews.com3 min
SEP 3
$APGEHighAI 9/10

Apogee Therapeutics, Inc. (APGE): Completion of Acquisition or Disposition of Assets

Apogee Therapeutics, Inc. (APGE) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Item 1.02 Termination of a Material Definitive Agreement. Effective as of the Effective Time, the Company terminated the Company’s 2023 Equity Incentive Plan and 2023 Employee Stock Purchase Plan. Item 2.01 Completion of Acquisition or Disposition of Assets. The disclosures in th

SEC EDGAR 8-K1 min
SEP 2
$MMEDMed

Biotech Stocks At 52-Week Highs - MMED +10%, PLSE, SOLV, RPRX, APGE

Several biotech stocks hit 52-week highs on September 1, 2026. MiniMed Group (MMED) rose 10% to $22.74 with 16.6% sales growth. Pulse Biosciences (PLSE) gained 3% to $54.39. Solventum (SOLV) reached $94.16 with 2.2% revenue growth. Royalty Pharma (RPRX) climbed to $62.58 with 14% royalty receipts growth. Apogee Therapeutics (APGE) hit $135.09 and will be acquired by AbbVie for $10.9B.

rttnews.com2 min